Compare Eli Lilly And Co (LLY) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs M&T Bank Corporation — how do they compare? Eli Lilly And Co trades at $1,177.75 (market cap $1.04T), while M&T Bank Corporation trades at $217.33 (market cap $31.42B). The key difference: Eli Lilly And Co is far larger — about 33.1× M&T Bank Corporation's market cap, and M&T Bank Corporation pays the higher dividend (2.76%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and M&T Bank Corporation for 100 Days on average.
| LLY | MTB | |
|---|---|---|
Market Cap | $1.04T | $31.42B |
Volume | 3,064,878 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $1.28K | $254.09 |
52-Week Low | $799.57 | $178.63 |
Typical Hold Time | 93 Days | 100 Days |
Enterprise Value | $1.09T | $47.77B |
Dividend Yield | 0.59% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
MTB trades at $217.49, up 0.41% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 11.52, net income margin of 30.85%, and three consecutive quarterly EPS beats. Recent news highlights loan growth, AI investments, and a new branch opening, while the company maintains a consistent dividend.
The outlook is mixed; analyst consensus is a Buy with a $258.92 price target, but technicals suggest near-term pressure. Key opportunities include earnings momentum and dividend stability, while risks involve cash flow volatility and high debt levels. The stock offers value but requires monitoring of upcoming Q3 2026 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
